Long-term follow-up from the phase 1/2a PLX120-03 study indicates durable responses with plixorafenib (PLX8394/FORE8394) in BRAF V600-altered primary CNS tumors. Data presented for a prespecified efficacy subgroup showed an 80% objective response rate in BRAF V600E high-grade gliomas and 50% in low-grade/glioma/neuronal tumors. Progression-free survival rates were reported at 56% at 12 months and 33% at 24 months. Investigators also reported no evidence of cumulative adverse effects with prolonged dosing, with some patients remaining on therapy for years, and additional responses when post-progression treatment included other MAPK inhibitors. The study is positioned as single-agent evidence for plixorafenib’s approach to inhibit BRAF V600 monomers and disrupt mutant dimers to avoid paradoxical pathway activation.